TABLE 3.
FQ and QRDR mutation | No. of isolates with MICa
|
||
---|---|---|---|
S | I | R | |
CIP | |||
None | 47 | 0 | 0 |
Single parC or gyrA mutation | 0 | 3 | 6 |
parC and gyrA mutations | 0 | 0 | 16 |
LVX | |||
None | 47 | 0 | 0 |
Single parC or gyrA mutation | 3 | 0 | 6 |
parC and gyrA mutations | 0 | 0 | 16 |
GAT | |||
None | 47 | 0 | 0 |
Single parC or gyrA mutation | 4 | 4 | 1 |
parC and gyrA mutations | 0 | 0 | 16 |
MXF | |||
None | 47 | 0 | 0 |
Single parC or gyrA mutation | 9 | 0 | 0 |
parC and gyrA mutations | 1 | 8 | 7 |
Abbreviations: S, susceptible; I, intermediate; and R, resistant. The CLSI MIC breakpoints were used for LVX (susceptible, ≤2 μg/ml; intermediate, 4 μg/ml; and resistant, ≥8 μg/ml), GAT (susceptible, ≤1 μg/ml; intermediate, 2 μg/ml; and resistant, ≥4 μg/ml), and MXF (susceptible, ≤1 μg/ml; intermediate, 2 μg/ml; and resistant, ≥4 μg/ml). The breakpoint standard for CIP was obtained from the interpretive guidelines supplied by the Japanese Society of Chemotherapy (susceptible, ≤1 μg/ml; intermediate, 2 μg/ml; and resistant, ≥4 μg/ml).